323 related articles for article (PubMed ID: 35311540)
1. Therapeutic Effects of Bifidobacterium breve YH68 in Combination with Vancomycin and Metronidazole in a Primary Clostridioides difficile-Infected Mouse Model.
Yang J; Meng L; Yang H
Microbiol Spectr; 2022 Apr; 10(2):e0067222. PubMed ID: 35311540
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the therapeutic effect and dose-effect of Bifidobacterium breve on the primary Clostridioides difficile infected mice.
Yang J; Yang H
Appl Microbiol Biotechnol; 2021 Dec; 105(24):9243-9260. PubMed ID: 34751791
[TBL] [Abstract][Full Text] [Related]
3. Combination of Bifidobacterium breve and antibiotics against Clostridioides difficile: effect of the time interval of combination on antagonistic activity.
Yang J; Li Y; Meng L
Int Microbiol; 2023 Nov; 26(4):833-840. PubMed ID: 36808573
[TBL] [Abstract][Full Text] [Related]
4. Effect of
Yang J; Yang H
Front Microbiol; 2018; 9():2953. PubMed ID: 30564210
[TBL] [Abstract][Full Text] [Related]
5. Antagonistic activity of selenium-enriched Bifidobacterium breve against Clostridioides difficile.
Rui W; Gu C; Zhang H; Liao X; Zhao X; Xu Y; Yang J
Appl Microbiol Biotechnol; 2022 Sep; 106(18):6181-6194. PubMed ID: 35962282
[TBL] [Abstract][Full Text] [Related]
6. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin.
Yamaguchi T; Konishi H; Aoki K; Ishii Y; Chono K; Tateda K
J Infect Chemother; 2020 May; 26(5):483-491. PubMed ID: 32165071
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial Activity of
Yang J; Yang H
Front Cell Infect Microbiol; 2019; 9():288. PubMed ID: 31440478
[No Abstract] [Full Text] [Related]
8. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.
Abujamel T; Cadnum JL; Jury LA; Sunkesula VC; Kundrapu S; Jump RL; Stintzi AC; Donskey CJ
PLoS One; 2013; 8(10):e76269. PubMed ID: 24098459
[TBL] [Abstract][Full Text] [Related]
9. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
[TBL] [Abstract][Full Text] [Related]
10. The Initial Gut Microbiota and Response to Antibiotic Perturbation Influence Clostridioides difficile Clearance in Mice.
Tomkovich S; Stough JMA; Bishop L; Schloss PD
mSphere; 2020 Oct; 5(5):. PubMed ID: 33087520
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
[TBL] [Abstract][Full Text] [Related]
12. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
Tashiro S; Taguchi K; Enoki Y; Matsumoto K
Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
[TBL] [Abstract][Full Text] [Related]
13. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
[TBL] [Abstract][Full Text] [Related]
14. Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.
Darkoh C; Keita K; Odo C; Oyaro M; Brown EL; Arias CA; Hanson BM; DuPont HL
Clin Infect Dis; 2022 Jan; 74(1):120-126. PubMed ID: 35016207
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
[TBL] [Abstract][Full Text] [Related]
16. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
17. Probiotics: insights and new opportunities for
Pal R; Athamneh AIM; Deshpande R; Ramirez JAR; Adu KT; Muthuirulan P; Pawar S; Biazzo M; Apidianakis Y; Sundekilde UK; de la Fuente-Nunez C; Martens MG; Tegos GP; Seleem MN
Crit Rev Microbiol; 2023 May; 49(3):414-434. PubMed ID: 35574602
[No Abstract] [Full Text] [Related]
18. Differences of the Fecal Microflora With Clostridium difficile Therapies.
Louie TJ; Byrne B; Emery J; Ward L; Krulicki W; Nguyen D; Wu K; Cannon K
Clin Infect Dis; 2015 May; 60 Suppl 2():S91-7. PubMed ID: 25922407
[TBL] [Abstract][Full Text] [Related]
19. The
Wickramage I; Peng Z; Chakraborty S; Harmanus C; Kuijper EJ; Alrabaa S; Smits WK; Sun X
Microbiol Spectr; 2023 Jun; 11(3):e0377722. PubMed ID: 37125917
[TBL] [Abstract][Full Text] [Related]
20. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
